1.97

4.79% 0.09

Nuvation Bio Inc (NUVB)

Overview News Price History Option Chain Discussions Forecast

Nuvation Bio Inc stock is traded at $1.97, with a volume of 2.96M. It is up +4.79% in the last 24 hours and down -5.74% over the past month. Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.

Previous Close:

$1.88

Open:

$1.9

24h Volume:

2.96M

Relative Volume:

1.11

Market Cap:

$686.13M

Revenue:

Net Income/Loss:

$-75.80M

P/E Ratio:

-5.6286

EPS:

-0.35

Net Cash Flow:

$-68.07M

1W Performance:

+12.57%

1M Performance:

-5.74%

6M Performance:

-18.93%

1Y Performance:

-26.77%

1-Day Range:

$1.885

$2.00

1-Week Range:

$1.7211

$2.08

52-Week Range:

$1.54

$3.97

Nuvation Bio Inc Stock (NUVB) Company Profile

Name

Nuvation Bio Inc

Sector

Healthcare (1151)

Industry

Biotechnology (660)

Phone

(415) 754-3517

Address

357 TEHAMA STREET, FLOOR 3, SAN FRANCISCO

Employee

220

Twitter

Next Earnings Date

2025-03-05

Latest SEC Filings

NUVB's Discussions on Twitter

Compare NUVB with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
NUVB Nuvation Bio Inc	1.97	686.13M	0	-75.80M	-68.07M	-0.35
VRTX Vertex Pharmaceuticals Inc	489.10	127.47B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	563.16	62.43B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	596.20	37.03B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	234.56	31.06B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	230.98	26.16B	3.81B	-644.79M	-669.77M	-6.24

Nuvation Bio Inc Stock (NUVB) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-27-24	Upgrade	Jefferies	Hold → Buy
Mar-26-24	Upgrade	BTIG Research	Neutral → Buy
Jan-06-23	Downgrade	Jefferies	Buy → Hold
Aug-02-22	Downgrade	BMO Capital Markets	Outperform → Market Perform
Aug-02-22	Downgrade	BTIG Research	Buy → Neutral
May-04-22	Initiated	H.C. Wainwright	Buy
Oct-15-21	Resumed	BTIG Research	Buy
Apr-06-21	Initiated	RBC Capital Mkts	Outperform
Mar-08-21	Initiated	BMO Capital Markets	Outperform
Mar-08-21	Initiated	BTIG Research	Buy
Mar-08-21	Initiated	Cowen	Outperform
Mar-08-21	Initiated	Jefferies	Buy
Mar-08-21	Initiated	Wedbush	Outperform

View All

Nuvation Bio Inc Stock (NUVB) Latest News

Apr 16, 2025

Is Nuvation Bio Inc. (NYSE:NUVB) the Best Biotech Penny Stock to Buy According to Hedge Funds? - Insider Monkey

Apr 16, 2025

Apr 13, 2025

Is Nuvation Bio Inc. (NUVB) the Top Healthcare Stock to Buy According to Billionaire David Einhorn? - Yahoo Finance

Apr 13, 2025

Wellington Management Group LLP Raises Position in Nuvation Bio Inc. (NYSE:NUVB) - Defense World

Apr 13, 2025

Nuvation Bio Inc. (NYSE:NUVB) Shares Acquired by Vanguard Group Inc. - Defense World

Apr 13, 2025

David Hung Buys 300,000 Shares of Nuvation Bio Inc. (NYSE:NUVB) Stock - MarketBeat

Apr 13, 2025

Apr 12, 2025

Corebridge Financial Inc. Cuts Stake in Nuvation Bio Inc. (NYSE:NUVB) - Defense World

Apr 12, 2025

Apr 11, 2025

American Century Companies Inc. Raises Stock Position in Nuvation Bio Inc. (NYSE:NUVB) - Defense World

Apr 11, 2025

Apr 10, 2025

KLP Kapitalforvaltning AS Acquires Shares of 43,500 Nuvation Bio Inc. (NYSE:NUVB) - Defense World

Apr 10, 2025

Apr 09, 2025